ScholarIQanswers from OpenAlex & ORCID
Jeffrey W. Clark
ResearcherPublications, citations & collaboration network
Jeffrey W. Clark is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jeffrey W. Clark have?
ScholarIQindexed works
Jeffrey W. Clark has 910 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jeffrey W. Clark have?
ScholarIQcitation count
Jeffrey W. Clark has 41,558 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jeffrey W. Clark?
ScholarIQh-index
Jeffrey W. Clark has an h-index of 90 in OpenAlex.
What is the i10-index of Jeffrey W. Clark?
ScholarIQi10-index
Jeffrey W. Clark has an i10-index of 272 in OpenAlex.
What is the ORCID of Jeffrey W. Clark?
ScholarIQorcid
The ORCID for Jeffrey W. Clark is on the source record.
What is the OpenAlex record for Jeffrey W. Clark?
ScholarIQopenalex
The OpenAlex for Jeffrey W. Clark is on the source record.
What are the most-cited papers on Jeffrey W. Clark?
ScholarIQmost cited works
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge, Alice T. Shaw, Benjamin Solomon, Robert G. Maki, Sai‐Hong Ignatius Ou, Bruce J. Dezube, Pasi A. Jänne, Daniel B. Costa, Marileila Varella‐Garcia, Woo Ho Kim, Thomas J. Lynch, Panos Fidias, Hannah Stubbs, Jeffrey A. Engelman, Lecia V. Sequist, Weiwei Tan, Leena Gandhi, Mari Mino–Kenudson, Greg C. G. Wei, S. Martin Shreeve, Mark J. Ratain, Jeffrey Settleman, James G. Christensen, Daniel A. Haber, Keith D. Wilner, Ravi Salgia, Geoffrey I. Shapiro, Jeffrey W. Clark, A. John Iafrate
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Sai‐Hong Ignatius Ou, Yung‐Jue Bang, D. Ross Camidge, Benjamin Solomon, Ravi Salgia, Gregory J. Riely, Marileila Varella‐Garcia, Geoffrey I. Shapiro, Daniel B. Costa, Robert C. Doebele, Long P. Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S. Martin Shreeve, L. Tye, James G. Christensen, Keith D. Wilner, Jeffrey W. Clark, A. John Iafrate
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon, Alice T. Shaw, Sai‐Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina T. Siwak-Tapp, Adriana González, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino–Kenudson, William Pao, A. John Iafrate
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak, A. John Iafrate, Marileila Varella‐Garcia, Stephen B. Fox, Gregory J. Riely, Benjamin Solomon, Sai‐Hong Ignatius Ou, Dong‐Wan Kim, Ravi Salgia, P. Fidias, Jeffrey A. Engelman, Leena Gandhi, Pasi A. Jänne, Daniel B. Costa, Geoffrey I. Shapiro, Patricia LoRusso, Katherine Ruffner, Patricia Stephenson, Yiyun Tang, Keith D. Wilner, Jeffrey W. Clark, Alice T. Shaw
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Alice T. Shaw, Beow Y. Yeap, Benjamin Solomon, Gregory J. Riely, Justin F. Gainor, Jeffrey A. Engelman, Geoffrey I. Shapiro, Daniel B. Costa, Sai‐Hong Ignatius Ou, Mohit Butaney, Ravi Salgia, Robert G. Maki, Marileila Varella‐Garcia, Robert C. Doebele, Yung‐Jue Bang, Kimary Kulig, Paulina Selaru, Yiyun Tang, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, A. John Iafrate, D. Ross Camidge